Skip to main content

Main menu

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • Other Publications
    • abfm

User menu

Search

  • Advanced search
American Board of Family Medicine
  • Other Publications
    • abfm
American Board of Family Medicine

American Board of Family Medicine

Advanced Search

  • HOME
  • ARTICLES
    • Current Issue
    • Ahead of Print
    • Archives
    • Abstracts In Press
    • Special Issue Archive
    • Subject Collections
  • INFO FOR
    • Authors
    • Reviewers
    • Call For Papers
    • Subscribers
    • Advertisers
  • SUBMIT
    • Manuscript
    • Peer Review
  • ABOUT
    • The JABFM
    • The Editing Fellowship
    • Editorial Board
    • Indexing
    • Editors' Blog
  • CLASSIFIEDS
  • JABFM On Twitter
  • JABFM On YouTube
  • JABFM On Facebook
Research ArticleOriginal Research

Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis

Neta Goldschmidt, Leora Zamir, Alina Poperno, Nathan R. Kahan and Ora Paltiel
The Journal of the American Board of Family Medicine November 2016, 29 (6) 702-709; DOI: https://doi.org/10.3122/jabfm.2016.06.150393
Neta Goldschmidt
the Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (NG, LZ, OP); the Enforcement and Inspection Division, Israeli Ministry of Health, Jerusalem, Israel (AP); the Medical Division, Leumit Health Services, Tel-Aviv, Israel (NRK); the School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel (NRK); and the School of Public Health, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (OP).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leora Zamir
the Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (NG, LZ, OP); the Enforcement and Inspection Division, Israeli Ministry of Health, Jerusalem, Israel (AP); the Medical Division, Leumit Health Services, Tel-Aviv, Israel (NRK); the School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel (NRK); and the School of Public Health, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (OP).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alina Poperno
the Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (NG, LZ, OP); the Enforcement and Inspection Division, Israeli Ministry of Health, Jerusalem, Israel (AP); the Medical Division, Leumit Health Services, Tel-Aviv, Israel (NRK); the School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel (NRK); and the School of Public Health, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (OP).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan R. Kahan
the Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (NG, LZ, OP); the Enforcement and Inspection Division, Israeli Ministry of Health, Jerusalem, Israel (AP); the Medical Division, Leumit Health Services, Tel-Aviv, Israel (NRK); the School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel (NRK); and the School of Public Health, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (OP).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ora Paltiel
the Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (NG, LZ, OP); the Enforcement and Inspection Division, Israeli Ministry of Health, Jerusalem, Israel (AP); the Medical Division, Leumit Health Services, Tel-Aviv, Israel (NRK); the School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel (NRK); and the School of Public Health, Hadassah-Hebrew University Medical Center, Jerusalem, Israel (OP).
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1.
    • Download figure
    • Open in new tab
    Figure 1.

    Flow chart for the calculation of time to diagnosis (TTD). ICR, Israel cancer registry; MM, multiple myeloma.

  • Figure 2.
    • Download figure
    • Open in new tab
    Figure 2.

    Overall survival according to time to diagnosis.

Tables

  • Figures
    • View popup
    Table 1.

    Durie-Salmon Stage, International Staging System Stage, and Survival Status According to Time to Diagnosis in Multiple Myeloma Cases

    DSS (n = 95)ISS Stage (n = 43)Survival Status (n = 98)
    IIIIIIIIIIIIAliveDead
    Patients, n (%)67 (71)18 (19)10 (10)28 (65)11 (25)4 (9)68 (69)30 (30)
    TTD (months)
        Mean ± SD10.8 ± 8.412.7 ± 9.313.4 ± 9.212.0 ± 9.114.0 ± 8.011.7 ± 9.711.1 ± 8.812.4 ± 8.5
        Median11.912.213.513.815.612.010.912.9
    Patients by TTD, n (%)
        >2 months19 (79)4 (17)1 (4)8 (80)1 (10)1 (10)18 (75)6 (25)
        2–12 months15 (63)5 (21)4 (16)4 (44.5)4 (44.5)1 (11)19 (73)7 (27)
        >12 months33 (70)9 (19)5 (11)16 (67)6 (25)6 (8.3)31 (65)17 (35)
    • DSS, Durie-Salmon stage; ISS, international staging system; SD, standard deviation; TTD, time to diagnosis.

    • View popup
    Table 2.

    Chief Complaint among 110 Cases with Multiple Myeloma, within the 2 Years before Diagnosis

    Main complaintPatients with the Symptom (at Least 1 Visit), n (%)Visits related to the Symptom, mean ± SD
    Pain complaint
        Back pain64 (58)3.0 ± 5.4
        Cervical spine pain33 (30)0.8 ± 1.7
        Musculoskeletal pain65 (59)2.6 ± 3.8
        Nonspecific pain37 (34)1.0 ± 3.2
        >1 Pain complaint25 (23)0.6 ± 1.4
        No pain complaint14 (13)
    Infections
        Viral infection61 (56)2.1 ± 2.7
        Bacterial infection52 (48)1.3 ± 2.3
    Weight loss10 (9)0.1 ± 0.46
    Fatigue27 (25)0.5 ± 1.3
    Other*36 (33)0.7 ± 1.4
    Abnormal laboratory test†35 (32)0.8 ± 2.2
    • ↵* “Other” includes peripheral edema, constipation, pre-syncope, syncope, and dizziness.

    • ↵† Patient's complaint was of an abnormal blood test.

    • SD, standard deviation.

    • View popup
    Table 3.

    Abnormal Blood Tests in the 2-Year Period before the Diagnosis of Multiple Myeloma among 110 Cases

    TestPatients Tested, nPatients with Abnormal Results, n (%)*
    Hemoglobin10068 (68)
    Calcium8514 (17)
    ESR6856 (82)
    Albumin8011 (14)
    Total protein8132 (39)
    Creatinine9226 (28)
    Proteinuria7631 (41)
    Uric acid8330 (36)
    • ↵* Abnormal results: hemoglobin <12.3 for women and <13.5 g/dL for men; calcium >10.2 mg/dL; erythrocyte sedimentation rate (ESR) >20 in the first hour; albumin <3.4 g/dL; total protein >8.7 g/dL; creatinine >1.1 for women and >1.2 mg/dL for men; proteinuria >10 mg/dL; uric acid >5.7 mg/dL.

    • ESR, erythrocyte sedimentation rate.

    • View popup
    Table 4.

    Comparison of Clinical Features of 79 Multiple Myeloma Cases and 79 Age-, Sex-, and Regionally Matched Controls

    Visits, Mean ± SDP Value
    PatientsControls
    Main complaint
        Back pain2.7 ± 4.12.9 ± 4.4.81
        Nonspecific pain1.2 ± 3.80.7 ± 1.4.28
        >1 Pain complaint0.6 ± 1.40.3 ± 0.8.11
        Viral infection1.4 ± 1.91.6 ± 2.4.59
        Bacterial infection1.2 ± 2.41.3 ± 1.8.81
        Weight loss/fatigue0.7 ± 1.50.1 ± 0.4.001
        Other nonspecific complaints0.7 ± 1.40.4 ± 0.5.05
        Abnormal laboratory test*0.7 ± 1.40.1 ± 0.6.001
    Abnormal Results, n
    PatientsControls
    Laboratory tests
        Anemia (n = 64)4417.001
        Elevated ESR (n = 20)164.001
        Renal failure (n = 63)227.001
        Proteinuria (n = 38)195.002
        Hypercalcemia (n = 42)80.005
        High total protein (n = 35)140<.001
        Hypoalbuminemia (n = 33)51.2
        Hyperuricemia(n = 45)1517.8
    • ↵* Anemia = hemoglobin <12.3 g/dL for women and <13.5 g/dL for men; elevated erythrocyte sedimentation rate (ESR) >20 in the first hour; renal failure = creatinine >1.1 mg/dL for women and >1.2 mg/dL for men; proteinuria = >10 mg/dL; hypercalcemia = calcium >10.2 mg/dL; high total protein = >8.7 g/dL; hypoalbuminemia = albumin <3.4 g/dL; hyperuricemia = uric acid >5.7 mg/dL.

    • ESR, erythrocyte sedimentation rate; SD, standard deviation.

    • View popup
    Table 5.

    Time to Diagnosis and Age

    Time to DiagnosisPatients, nAge (years)
    Mean ± SDMedianRange
    <2 months3060.1 ± 11.9*60.534–79
    2–12 months2863 ± 8.6*6338–79
    >12 months4966.3 + 10.3*6547–88
    • ↵* P = .04.

    • SD, standard deviation.

PreviousNext
Back to top

In this issue

The Journal of the American Board of Family     Medicine: 29 (6)
The Journal of the American Board of Family Medicine
Vol. 29, Issue 6
November-December 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Board of Family Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis
(Your Name) has sent you a message from American Board of Family Medicine
(Your Name) thought you would like to see the American Board of Family Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 9 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis
Neta Goldschmidt, Leora Zamir, Alina Poperno, Nathan R. Kahan, Ora Paltiel
The Journal of the American Board of Family Medicine Nov 2016, 29 (6) 702-709; DOI: 10.3122/jabfm.2016.06.150393

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis
Neta Goldschmidt, Leora Zamir, Alina Poperno, Nathan R. Kahan, Ora Paltiel
The Journal of the American Board of Family Medicine Nov 2016, 29 (6) 702-709; DOI: 10.3122/jabfm.2016.06.150393
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusion
    • Notes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report
  • Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels
  • Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis
  • Re: Presenting Signs of Multiple Myeloma and the Effect of Diagnostic Delay on the Prognosis
  • Bread and Butter of Family Medicine: Guidelines, Population Screening, Diagnostic Evaluations, and Practice Models
  • Google Scholar

More in this TOC Section

  • Impact of a Pharmacist-Run Electronic Consult Service in a Network of Primary Care Patient-Centered Medical Homes
  • Integrating Harm Reduction into Medical Care: Lessons from Three Models
  • An Estimate of Severe Harms Due to Screening Colonoscopy: A Systematic Review
Show more Original Research

Similar Articles

Keywords

  • Anemia
  • Back Pain
  • Creatinine
  • Early Detection of Cancer
  • Electronic Health Records
  • Health Maintenance Organizations
  • Multiple Myeloma
  • Primary Health Care
  • Prognosis
  • Retrospective Studies
  • Weight Loss

Navigate

  • Home
  • Current Issue
  • Past Issues

Authors & Reviewers

  • Info For Authors
  • Info For Reviewers
  • Submit A Manuscript/Review

Other Services

  • Get Email Alerts
  • Classifieds
  • Reprints and Permissions

Other Resources

  • Forms
  • Contact Us
  • ABFM News

© 2023 American Board of Family Medicine

Powered by HighWire